NEW YORK — Sano Genetics said on Thursday that it has partnered with Patients Know Best, a UK online medical records system developer, and British drug discovery firms BenevolentAI and C4X Discovery to develop a database for ulcerative colitis research.
The effort, which is being funded in part with a £330,000 ($450,850) grant from Innovate UK, will combine patients' genetic and transcriptomic data with their electronic medical records and self-reported information, according to Sano.
Participants will be able to use Sano's data-sharing platform to access and control their data, which will be analyzed using C4X's Taxonomy3 platform to identify novel drug targets and patient subtypes.
Additional details about the alliance were not disclosed.
"This unique project will not only allow us to advance our precision medicine approaches, but the new database will provide a game-changing resource for the development of new treatments for ulcerative colitis," Mark Davies, senior vice president of informatics and data at BenevolentAI, said in a statement.
In January, Cambridge, England-based Sano raised £2.5 million in seed funding, which it said would support its efforts to provide free at-home DNA testing kits to individuals affected by chronic, long-term effects of SARS-CoV-2 infection.